CST: 01/07/2016 17:31:14   

Endonovo Therapeutics Receives USPTO Notice of Allowance for Patent Covering Production of Biomolecules From Adult Stem Cells

93 Days ago

Endonovo Adds Production of Biological Molecules From Adult Stem Cells to Its Patent Licensing Program

LOS ANGELES, CA--(Marketwired - Mar 30, 2016) - Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), an innovative biotechnology company developing bioelectronics-based products and therapies for regenerative medicine, announced today it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application entitled "Biological Molecules Produced by Electromagnetically Stimulating Living Mammalian Cells."

The patent application covers the production of biological molecules, including growth factors and cytokines in adult stem cells using the Company's proprietary technologies. This Notice of Allowance concludes substantive examination of the patent application and is expected to result in the issuance of a U.S. patent in the near future.

The Company has added this technology to its patent licensing program as it begins to pursue potential revenue producing applications of its portfolio of intellectual property.

Endonovo Chairman and CEO, Alan Collier commented, "we are excited about the issuance of this patent covering the production of biological molecules from adult stem cells, which can be used to produce human proteins." Conventional methods of protein production include recombinant techniques used with bacteria or CHO cells.

According to Thomson Reuters, the biologics sector is set for an unprecedented level of activity as U.S. companies have rapidly increased their biologics development during the past five years. The market for next-generation biologics is estimated to reach a value of $30 billion by 2024, according to Visiongain. These next-generation biologics will seek to address shortcomings in current therapies, including inconvenient dosing and potential side-effects.

"Some applications from this technology include the production of biomolecules for research purposes or the potential production of next-generation biologics. "We are interested in potentially licensing this technology or partnering with a larger pharmaceutical/drug company to develop it," concluded Mr. Collier.

About Endonovo Therapeutics

Endonovo Therapeutics, Inc. is an innovative biotechnology company developing bioelectronic devices and therapies for regenerative medicine. Endonovo's Immunotronics™ platform is a non-invasive, non-implantable bioelectronic device for treating/preventing vital organ failure through the reduction of inflammation, cell death and the promotion of regeneration. Endonovo's Cytotronics™ platform provides for a method of expanding and manipulating cells using simulated microgravity and Time-Varying Electromagnetic Fields (TVEMF) for tissue engineering and cell therapies. The Company's initial concentration is on the treatment of acute and chronic inflammatory conditions of the liver using its proprietary Immunotronics™ platform.

Safe Harbor Statement

This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.

Investors: Sign Up for Email Alerts on Endonovo

Investor Relations Contact:
Endonovo Therapeutics, Inc.
Mr. Steven Barnes
Vice President of Investor Relations
(800) 701-1223, Ext. 108
Sbarnes@endonovo.com
www.endonovo.com